Biochemical Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors by Cardiovascular Risk Profile and Volume Status in a Real-World Diabetic Population-Reference-Cited by-同舟云学术

Biochemical Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors by Cardiovascular Risk Profile and Volume Status in a Real-World Diabetic Population

Published:2022-05-06 Issue:1 Volume:80 Page:140-147
ISSN:0160-2446
Container-title:Journal of Cardiovascular Pharmacology
language:en
Short-container-title:

Author:

Gitto Mauro,Kotinas Alexios S.,Terzi Riccardo,Oliva Angelo,Zagoreo Jorgele,Reimers Bernhard,Stefanini Giulio G.,Mirani Marco,Favacchio Giuseppe,Condorelli Gianluigi,Panico Cristina

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

Reference36 articles.

1. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants;Danaei;Lancet,2011

2. Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies;Kenny;Circ Res.,2019

3. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study;Stratton;BMJ,2000

4. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med.,2015

5. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med.,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure;Current Pharmaceutical Design;2023-02